NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX)
(FSE: J90) (NRX.V), is pleased to report positive imaging results
from an internal preclinical study of its investigational drug
ExoPTEN. The image analysis and measurements confirmed successful
nerve regeneration following traumatic transection of the spinal
cord in rats. These imaging results align with previous results
showing a remarkable recovery of motor function in 75% of paralyzed
rats suffering from spinal cord injuries and treated with the new
therapy.
During a recent internal preclinical trial, the
company's ExoPTEN drug caused 75% of rats to regain hind limb
reflex, some motor function, and sensory control. Subsequently, the
spinal cords of rats from the study were subjected to advanced
Diffusion Tensor Imaging (DTI) to assess the structural integrity
of the spinal cord. Our DTI analysis yielded representative
observations for different rat groups as follows:
- Intranasal ExoPTEN
with recovered motor function – Reinnervation, indicating a
restoration of nerve supply to the spinal cord below the
transection. (Fig.1A)
- Control group -
Atrophied and de-innervated spinal cord below the transection
(Fig.1A)
- A healthy spinal
cord, without trauma, is included as a reference for
comparison. (Fig.1A)
DTI was performed using conventional magnetic
resonance imaging (MRI) and diffusion tensor imaging techniques.
Furthermore, fractional anisotropy (FA) measurements were used for
a quantitative assessment of tissue integrity. The results showed
higher FA values indicating reduced tissue microstructural damage
in the caudal region of the ExoPTEN-treated rats compared to the
control SCI group (Fig. 1B). A range of healthy rat FA values from
a separate experiment is included in Fig. 1B for reference. It is
important to note that the nerves below the lesion site presented
better survival and less degeneration, which is one of the common
pathophysiological conditions after injury.
ExoPTEN is being developed to be a minimally
invasive ExoTherapy for spinal cord injuries (SCI) administrated
intranasally and yielding neuron regeneration and rewiring in
traumatically damaged spinal cords. The drug is being developed
using NurExone's proprietary ExoTherapy platform for producing and
loading exosomes with pharmaceutical cargo targeting central
nervous system injuries.
"We are delighted to receive promising results
from this study, which demonstrated reinnervation as a result of
our ExoPTEN product," said Dr. Lior Shaltiel, Chief Executive
Officer. "Moreover, it validates the functional recovery we
observed with non-invasive administration of our investigational
ExoPTEN drug. We are eager to advance our research and clinical
trials to translate these results to the millions of human patients
in need."
Figs. 1A-B Diffusion Tensor Imaging and
MeasurementsStructural Integrity of the Caudal
Spinal Cord
Figure Legend:(A) To assess the structural
integrity of the spinal cord, 9.4T conventional MRI and diffusion
tensor imaging (DTI) was performed in control-treated (IN) SCI
animals, ExoPTEN-treated (IN) SCI animals, and intact rats. In the
control-treated SCI animals, caudal nerve tracts were completely
severed at the epicenter indicated, leaving the caudal spinal cord
de-innervated and atrophied. ExoPTEN promoted reinnervation and
nourishment to the caudal spinal cord.
(B) Fractional anisotropy (FA) is a measure of
tissue integrity. Thus, FA decreases with tissue
microstructural damage. FA recordings caudal to the injury
site were higher in ExoPTEN-treated rats compared to the control
SCI group (B). The green area represents the range of healthy rats'
FA values as obtained in a separate experiment. These DTI
tractography images and measurements indicate re-innervation and
nourishment to the caudal spinal cords in ExoPTEN rats treated
intranasally.
About NurExone
Biologic Inc.
NurExone Biologic Inc. is a TSX Venture
Exchange-listed pharmaceutical company that is developing a
platform for biologically-guided ExoTherapy to be delivered,
non-invasively, to patients who suffered traumatic spinal cord
injuries.
ExoTherapy was conceptually demonstrated in
animal studies at the Technion, Israel Institute of Technology.
NurExone is translating the treatment to humans, and the Company
holds an exclusive worldwide license from the Technion and Tel Aviv
University for the development and commercialization of the
technology.
For additional information, please
visit www.nurexone.com or follow NurExone
on LinkedIn, Twitter, Facebook,
or YouTube.
For further
information, please
contact:
Dr. Lior ShaltielChief Executive Officer and
Director Phone: +972-52-4803034
Inbar Paz-BenayounAdv. Head of Communications
and Investor Relations Phone: +972-52-3966695Email:
info@nurexone.com
Investor Relations (Canada) Phone: +1
905-347-5569Email: IR@nurexone.com
To download NurExone's Earnings
Presentation, please
visit:https://nurexone.com/wp-content/uploads/2023/03/Nurexone-Q4-Full-Year-Fiscal-2022-Financial-Results-March-2023.pdf
FORWARD-LOOKING
STATEMENTS
This press release contains "forward-looking
statements" that reflect the Company's current expectations and
projections about its future development. When used in this press
release, forward-looking statements can be identified by the use of
words such as "may," or by such words as "will," "intend,"
"believe," "estimate," "consider," "expect," "anticipate," and
"objective" and similar expressions or variations of such words.
Forward-looking statements are, by their nature, not guarantees of
the Company's future operational or financial performance and are
subject to risks and uncertainties and other factors that could
cause the Company's actual results, performance, prospects, or
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements. No representation or
warranty is intended with respect to anticipated future results, or
that estimates, or projections will be sustained.
Forward-looking statements are necessarily based
on estimates and assumptions made by us in light of our experience
and perception of historical trends, current conditions, and
expected future developments, as well as the factors we believe are
appropriate. Forward- looking statements in this press release
include, but are not limited to, statements relating to: our future
plans and intellectual property; our scientific and development
activities and the results of our internal pre-clinical trial;
future scientific activities and the treatment of certain
conditions; the therapeutic benefits, effectiveness, and safety of
our product candidates; and the estimated growth of the market for
acute spinal cord injuries.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including that the internal pre-clinical trial represents reliable
results, our ability to retain key personnel, our ability to
continue investing in research and development, our ability to
secure available funding and to continue as a going concern, the
general business and economic conditions of the industries and
countries in which we operate, and our ability to execute on our
business strategy.
Many risks, uncertainties, and other factors
could cause the actual results of the Company to differ materially
from the results, performance, achievements, or developments
expressed or implied by such forward-looking statements. These
risks, uncertainties, and other factors include, but are not
limited to, the following: those risk factors identified under the
heading "Risk Factors" on pages 29 to 36 of the Company's Annual
Information Form dated March 30, 2023, a copy of which is available
under the Company's SEDAR profile at www.sedar.com; risks related
to the Company's early stage of development; lack of revenues to
date; government regulation; market acceptance for our products;
rapid technological change; dependence on key personnel; protection
of our intellectual property; dependence on our strategic partners;
overall economic conditions; competitive pressures; network
restrictions; and other similar factors that may cause the actual
results, performance or achievements to differ materially from
those expressed or implied in these forward-looking statements.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of the
press release or as of the date otherwise specifically indicated
herein. Due to risks and uncertainties, events may differ
materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as required pursuant to applicable securities
law. All forward-looking statements contained in the press release
are expressly qualified in their entirety by this cautionary
statement. Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4ae39821-dc27-47be-b5bb-18ae8a0245e8
Nurexone Biologic (TSXV:NRX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Nurexone Biologic (TSXV:NRX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024